GCL vs. IBT, MNP, BOOK, JMC, GRID, CCJI, ASLI, GSF, WPC, and JETI
Should you be buying Geiger Counter stock or one of its competitors? The main competitors of Geiger Counter include International Biotechnology (IBT), Martin Currie Global Portfolio (MNP), Literacy Capital (BOOK), JP Morgan Chinese Investment Trust (JMC), Gresham House Energy Storage (GRID), CC Japan Income & Growth (CCJI), abrdn European Logistics Income (ASLI), Gore Street Energy Storage Fund (GSF), Witan Pacific Investment Trust PLC (WPC.L) (WPC), and JPMorgan European Investment Trust Income Pool (JETI). These companies are all part of the "asset management" industry.
Geiger Counter vs.
Geiger Counter (LON:GCL) and International Biotechnology (LON:IBT) are both small-cap financial services companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.
Geiger Counter has a net margin of 135.81% compared to International Biotechnology's net margin of 90.66%. International Biotechnology's return on equity of 13.67% beat Geiger Counter's return on equity.
International Biotechnology received 106 more outperform votes than Geiger Counter when rated by MarketBeat users. Likewise, 77.71% of users gave International Biotechnology an outperform vote while only 58.82% of users gave Geiger Counter an outperform vote.
International Biotechnology has higher revenue and earnings than Geiger Counter. Geiger Counter is trading at a lower price-to-earnings ratio than International Biotechnology, indicating that it is currently the more affordable of the two stocks.
In the previous week, International Biotechnology had 3 more articles in the media than Geiger Counter. MarketBeat recorded 4 mentions for International Biotechnology and 1 mentions for Geiger Counter. International Biotechnology's average media sentiment score of 1.37 beat Geiger Counter's score of 0.59 indicating that International Biotechnology is being referred to more favorably in the news media.
Geiger Counter has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, International Biotechnology has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500.
25.7% of Geiger Counter shares are held by institutional investors. Comparatively, 45.2% of International Biotechnology shares are held by institutional investors. 0.2% of Geiger Counter shares are held by company insiders. Comparatively, 4.2% of International Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
International Biotechnology beats Geiger Counter on 12 of the 15 factors compared between the two stocks.
Get Geiger Counter News Delivered to You Automatically
Sign up to receive the latest news and ratings for GCL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Geiger Counter Competitors List
Related Companies and Tools
This page (LON:GCL) was last updated on 2/22/2025 by MarketBeat.com Staff
Free GCL Stock Alerts